5-Amino-1MQ Before and After: Research Timelines

The most-shared 5-Amino-1MQ before and after images online have one thing in common: not a single one comes from a published trial. The compound's entire documented outcomes record sits in rodent work, and there the timelines are measured in days, not months.

We supply this compound to research laboratories, and time-to-effect is the single most common question our team fields about it. Here is what the literature documents, and what it doesn't.

'How long to see results from 5-Amino-1MQ, and what do before and after comparisons show?'

In published rodent research, 5-Amino-1MQ before and after comparisons showed reductions in body weight and white adipose tissue mass across roughly an 11-day daily administration window, with food intake unchanged. Biochemical effects on NNMT activity precede that by days. No peer-reviewed human clinical trial timeline exists for this compound.

The common oversimplification is that 5-Amino-1MQ before and after results describe a weight-loss timeline. They don't. The rodent studies tracked enzyme inhibition, body composition and food intake as separate instrumented endpoints, and those endpoints move on different clocks. What follows covers the documented observation windows, why adipose mass shifts before scale weight does, and how to read before-and-after claims that carry no data behind them.

What the published research actually measured, and when

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase, or NNMT: the enzyme that transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. NNMT is heavily overexpressed in the white adipose tissue of obese animal models, which is why it became a metabolic target at all.

The foundational paper came from Kraus and colleagues in Nature in 2014, using antisense oligonucleotide knockdown of NNMT in diet-induced obese mice. Knocking the enzyme down protected against fat mass gain, and it did so without reducing how much the animals ate. The small-molecule follow-up is what matters for timing questions. Neelakantan and colleagues, publishing in Biochemical Pharmacology in 2018, characterised membrane-permeable quinolinium NNMT inhibitors including 5-amino-1MQ and reported that daily administration across an 11-day window reduced body weight and adipose mass in diet-induced obese mice.

Eleven days. That is the shortest well-documented window in which a phenotype change was reported, and it is the closest thing to an honest answer anyone can give on how long to see results from 5 amino 1MQ in a controlled research model. Anyone typing 5-Amino-1MQ before and after into a search bar is really asking about that window.

Our team has watched labs build a study around one four-week body-weight readout, see nothing early, and write the compound off. The compound wasn't the problem. The measurement schedule was.

Why fat mass moves before the scale does

Enzyme inhibition and body composition change are not the same event, and they don't happen at the same speed. Blocking NNMT preserves nicotinamide for the NAD+ salvage pathway, where the enzyme NAMPT recycles it back into NAD+, while also sparing intracellular SAM for other methylation and polyamine flux inside the adipocyte. Those biochemical shifts are detectable within hours to days in cell and tissue models. Mass change is downstream of them by a week or more.

This is also why 5-Amino-1MQ before and after comparisons look nothing like GLP-1 receptor agonist data. Semaglutide and tirzepatide act through appetite signalling and delayed gastric emptying, so caloric intake falls quickly and scale weight follows. NNMT inhibition in the rodent work did not reduce food intake. The reported change was attributed to adipocyte energy handling, which means lean mass tends to be preserved and total scale weight understates what body composition analysis picks up.

Here is the detail most write-ups skip entirely. The quinolinium scaffold that inhibits NNMT is a permanently charged cation, and permanently charged molecules cross cell membranes poorly. The 5-amino substitution exists specifically because it improved membrane permeability enough for the compound to reach intracellular NNMT in the first place. So purity and structural integrity aren't cosmetic concerns here. A degraded or mis-synthesised analog may still bind the enzyme in a tube and never get inside a cell, and a research team would read that as compound failure when it is actually material failure.

Reading 5-Amino-1MQ before and after claims critically

Nearly every 5-Amino-1MQ before and after picture circulating on forums and social platforms is an uncontrolled anecdote presented as a result. No baseline body composition measurement. No food intake record. No control subject on the same diet. And, most often, no independent confirmation that the material in the vial was 5-amino-1MQ at the purity printed on the label.

Three questions separate a data point from a photograph. Was the starting state measured with something other than a camera? Was intake recorded or held constant? Was the compound identity-confirmed by mass spectrometry and purity-confirmed by HPLC on a third-party certificate of analysis? Published 5-amino-1MQ results answer all three. A before-and-after image answers none of them.

That third question is the only one a supplier can answer, and it is the one we take most seriously. Every batch of 5-Amino-1MQ we release is small-batch synthesised and released against third-party documentation of identity and purity, because a null result from unverified material tells a researcher nothing at all.

These compounds are supplied for laboratory research only. They are not FDA-approved drugs, they are not intended for human or veterinary consumption, and any question about the health of a person or an animal belongs with a licensed physician or a licensed veterinarian rather than a supplier, a forum thread or an article like this one. Study design and handling decisions sit with qualified investigators.

Observation windows: what changes when

Different endpoints become measurable at very different points, and conflating them is the main reason timeline expectations go wrong. This table maps what the research record supports at each stage against what a camera could realistically capture.

What If: Research Timeline Scenarios

What if the before-and-after photos I found online look dramatic?

Treat them as marketing artefacts until a measured baseline exists behind them. The 5-Amino-1MQ before and after pictures shared on social platforms have no body composition scan, no recorded intake, no independent verification that the vial contained what the label claimed, and no comparison subject held on the same diet. Lighting, posture, hydration status and time of day shift apparent body composition more than two weeks of almost any metabolic intervention would in a controlled rodent model. The published work used instrumented tissue measurement precisely because the eye cannot make that distinction.

What if a research model shows no measurable change after fourteen days?

Check the endpoint before questioning the compound. Body weight is a blunt, late-arriving readout, and in the published rodent literature it was reported alongside white adipose tissue mass, which is the more sensitive measure of the two. Assay-level endpoints such as 1-methylnicotinamide output or tissue NAD+ levels respond considerably earlier. A study designed around scale weight alone can miss real enzymatic activity completely, then record a false negative that follows the compound around in citation trails for years.

What if the compound arrived without a certificate of analysis?

Stop and request documentation before any work begins. Identity and purity for a quinolinium small molecule should be established by mass spectrometry and HPLC on a third-party report, not asserted on a printed label. Without that paperwork a null result is uninterpretable, because you cannot distinguish an inactive compound from a degraded one, a mis-synthesised analog, or a vial at a different concentration than stated. Unverified material doesn't produce a weak study. It produces an uninterpretable one.

The uncomfortable truth about before-and-after photos

Let's be direct about this: there is no verified human 5-Amino-1MQ before and after dataset anywhere in the peer-reviewed literature, and anyone presenting one as clinical evidence is selling something. The compound has a genuinely interesting mechanism and a real, replicated preclinical literature behind NNMT as a metabolic target. That is not the same thing as an established human timeline, an established effect size, or a characterised safety profile. Preclinical promise and human evidence are separated by years of trial work that has not been done for this molecule.

Researchers comparing suppliers can review batch documentation on our certificates of analysis page, browse current catalog availability across the full research compound range, and read more about where and how we operate on our location page.

Every 5-Amino-1MQ before and after image you will find online is a claim without a control group, and once that lands, the whole question changes shape. The useful question was never how fast something shows up in a mirror. It is which endpoint you are measuring, on what instrument, at what interval, against what comparison. Eleven days in a mouse study meant something specific because everything surrounding those eleven days was held constant. A photograph holds nothing constant at all.